Contents
Editor’s Letter
Latest features in GaBI Journal, 2015, Issue 3
Editorial
Advances in analytical characterization of biosimilars
Letters to the Editor
Access to safe and effective biopharmaceuticals
Commentary
The challenges of nomenclature – INN, biosimilars and biological qualifiers
Review Article
Biosimilars patent litigation in the EU and the US: a comparative strategic overview
Biosimilars: extrapolation of clinical use to other indications
Perspective
The implementation of generics in France
Substantial savings with generics in Austria – and still room for more
Meeting Report
European biosimilars conference highlights extrapolation as key issue
Regulatory
Regulatory requirements for the development and registration of biosimilars in South Africa